Notably, these effects were abolished by pretreatment with the cAMP inhibitor SQ22536 in cellular models and the PKA inhibitor H‐89 in mice, demonstrating that the cAMP/PKA/CREB axis mediates EUG's beneficial effects on NAFLD. Here, CREB1 is linked to metabolic dysfunction-associated steatotic liver disease.